Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, toward Phase 2 clinical trials following promising Phase 1 safety data. The therapy is designed to target demyelination and protect or restore myelin integrity, offering a potentially first-in-class approach that directly addresses myelin loss and neurodegeneration rather than relying solely on immune modulation.
Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated. These results support the advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists. Quantum BioPharma believes LUCID-MS may offer a differentiated approach to treating multiple sclerosis by directly addressing the underlying mechanisms of the disease.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets the OTC version of unbuzzd, and receives royalty payments of 7% of sales until reaching $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For more information, visit the company's newsroom at https://ibn.fm/QNTM. The full article on Quantum BioPharma's developments is available at https://ibn.fm/AUhNl.
